Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × ivosidenib × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2 Gastrointestinal 2 Tumor-Agnostic 1 CNS 1

Conditions

Interventions

Temozolomide 155 Bevacizumab 97 Radiotherapy 79 Radiation 35 Cyclophosphamide 34 Irinotecan 32 Carboplatin 32 Magnetic Resonance Spectroscopy 30 Etoposide 29 Radiosurgery 24 Vincristine 22 pembrolizumab 21 Nivolumab 20 Radiotherapy, Intensity-Modulated 18 Isotretinoin 18 Filgrastim 18 Cisplatin 18 Topotecan 17 Everolimus 17 Erlotinib Hydrochloride 16 Vorinostat 15 Doxorubicin 15 sargramostim 14 Lomustine 14 Granulocyte Colony-Stimulating Factor 14 Radiotherapy, Conformal 12 antineoplaston AS 2-1 11 antineoplaston A10 11 Immunoglobulin G 11 Disulfides 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04056910 2025-02-27

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

University of Pittsburgh

Phase 2 Completed

15 enrolled 14 charts

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡